Pay in 4 interest-free payments of $6.71 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
RGN-352 was shown to be safe and well-tolerated with no serious drug-related adverse events reported (PMID: 20536472) Phase 2 AMI trial (incomplete): RegeneRx designed a Phase 2 proof-of-concept trial (NCT01311518) to evaluate RGN-352 in approximately 75 patients with acute ST-segment elevation myocardial infarction (heart attack)
Date ENHANCED EXTENDS PEPTIDE PLATFORM WITH TOPICAL GHK-CU, FORMULATED UNDER MEDICAL COMMISSION OVERSIGHT -- Prescription Topical Peptide Delivers a Consistent, Clinician-Prescribed Dose of GHK-Cu in Each Application -- -- Available Now on the Live Enhanced Platform -- New York April 28, 2026 Enhanced today announced an exciting new addition to its peptide catalog with the launch of a prescription-dosed topical GHK-Cu cream
Drugs, route of administration, indication, distribution channel, end-user, and geography segment the Latin America glucagon-like peptide-1 (GLP-1) agonists market
Metabolism 2010;59:123-133
.jpg)